Khawplod Pakamatz, Wilde Henry, Sirikwin Siriwan, Benjawongkulchai Maneerat, Limusanno Sukunya, Jaijaroensab Wipaporn, Chiraguna Napha, Supich Chalida, Wangroongsarb Yongyuth, Sitprija Visith
Queen Saovabha Memorial Institute, Thai Red Cross Society, 1871 Rama IV Road, Bangkok 10330, Thailand.
Vaccine. 2006 Apr 12;24(16):3084-6. doi: 10.1016/j.vaccine.2006.01.051. Epub 2006 Feb 8.
The Thai Red Cross intradermal post-exposure rabies prophylaxis regimen (TRC-ID) is being used in Thailand, the Philippines, Sri Lanka and is making inroads in India. It consists of two injections of 0.1 mL of any World Health Organization recommended tissue culture rabies vaccine intradermally at two sites on days 0, 3, 7, followed by one injection on days 28 and 90. Two decades of experience had shown that approximately 11% of 187,000 possibly rabies exposed subjects who received the TRC-ID schedule, did not return for the 90-day booster. No rabies deaths had, however, been reported from this group. This stimulated two studies to determine whether the 90-day booster can be abolished. They demonstrated that, if the single 28-day 0.1 mL injection is increased to two at two sites, a comparable antibody response can be achieved and the 90-day booster can be omitted. The tissue culture rabies vaccine used in the preliminary study was purified chick embryo vaccine (PCEC Chiron) and for this study it was chromatography purified Vero cell vaccine (CPRV, Aventis-Pasteur). CPRV had been previously shown to be as immunogenic and effective as purified Vero cell rabies vaccine (PVRV).
泰国红十字会皮内暴露后狂犬病预防方案（TRC-ID）在泰国、菲律宾、斯里兰卡得到应用，并正在进入印度。该方案包括在第0、3、7天于两个部位皮内注射0.1毫升任何世界卫生组织推荐的组织培养狂犬病疫苗，共注射两次，随后在第28天和第90天各注射一次。二十年的经验表明，在18.7万名可能暴露于狂犬病的受试者中，约11%接受了TRC-ID方案，但未返回进行90天的加强注射。然而，该组未报告狂犬病死亡病例。这促使进行了两项研究，以确定是否可以取消90天的加强注射。研究表明，如果将第28天的单次0.1毫升注射增加到在两个部位各注射两次，可获得类似的抗体反应，且可省略90天的加强注射。初步研究中使用的组织培养狂犬病疫苗是纯化鸡胚细胞疫苗（PCEC，Chiron公司生产），本研究中使用的是经色谱纯化的Vero细胞疫苗（CPRV，安万特-巴斯德公司生产）。此前已证明CPRV与纯化Vero细胞狂犬病疫苗（PVRV）具有相同的免疫原性和有效性。
